Celecoxib 化学構造
分子量: 381.37

高品質保証

カスタマーフィードバック(2)

Quality Control & MSDS

製品説明

  • Compare COX Inhibitors
    COX製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 セレコキシブは、40nMのIC50による選択的なCOX-2阻害剤です。
ターゲット COX-2
IC50 40 nM [1]
In vitro試験 Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A549 M1XQfGZ2dmO2aX;uJGF{e2G7 NET0NI8xNjFvM{Cg{txO MV60PEBp M2DuPIlv\HWlZYOgTWNCVS1zIHX4dJJme3Orb36gc44h[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVt M1O1SlI3PTF|MUey
H460 NVzhSGtUTnWwY4Tpc44hSXO|YYm= MWqwMlEuOzBizszN MX60PEBp NVn5U49tcW6mdXPld{BKS0GPLUGg[ZhxemW|c3nvckBwdiCkb4ToJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wx? Mo[1NlY2OTNzN{K=
HKESC-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVGyNOKh|ryP MWS0POKhcMLi MUXzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgTWM2OMLidnHseYV{KG:oIH;4ZYxqeGyjdHnuxsA> M2f6elI3PDd2Nkmz
CaES-17 NIfqRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\i[mZROjEEoN88US=> MkHJOFjDqGkEoB?= Mnrud4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJGlEPTEEoI\hcJVmeyCxZjDvfIFtcXCuYYTpcuKh M4DkSlI3PDd2Nkmz
HKESC-2 M4jlc2Fxd3C2b4Ppd{BCe3OjeR?= MVWyNOKh|ryP NIDsWYU1QMLiaNMg NUnDVZh{emWmdXPld{BwgGGuaYDsZZRqdi2rbnT1Z4VlKGGyb4D0c5Nqew>? NVXqeJpKOjZ2N{S2PVM>
CaES-17 MnvpRZBweHSxc3nzJGF{e2G7 NXrNfHZPOjEEoN88US=> NEfGRW01QMLiaNMg MnzPdoVlfWOnczDvfIFtcXCuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> MXSyOlQ4PDZ7Mx?=
A549 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTSeVVCPS1zNkCg{txO NYq4RmFmPDkEoHlCpC=> MUjEUXNQ MorGTWM2OD1zNkOuOEDPxE1? NFrFfZUzPjR4NE[0Ny=>
HCC827 Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jD[|UuOTZyIN88US=> MYi0POKhcMLi NWLHZ5p7TE2VTx?= NVS0WndlUUN3ME22PU4zKM7:TR?= M4nBNFI3PDZ2NkSz
A549 MYLBdI9xfG:|aYOgRZN{[Xl? NHfGXHM5OCEEtV2= NF;JPWo1QMLiaNMg NXe4PHF1TE2VTx?= MYTpcoR2[2W|IHHwc5B1d3Orcx?= M3fDZVI3PDZ2NkSz
HCC827 M1\WcWFxd3C2b4Ppd{BCe3OjeR?= Moi2PFAhyrWP MnrpOFjDqGkEoB?= NFLH[pBFVVOR M1HBXIlv\HWlZYOgZZBweHSxc3nz M3niZVI3PDZ2NkSz
SGC-7901/DDP MnKxSpVv[3Srb36gRZN{[Xl? NFPwSoIyOMLiwsXN MmXxNlQhcA>? M170[olvcGmkaYTzJIN6[2yxb4j5[4Vv[XOnLUKgZY5lKFBvZ3z5Z49xem:2ZXnuJIV5eHKnc4Ppc44> MnrsNlY1ODd4NUO=
SGC-7901  Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHP2U3AzPMLiaNMg M3ixfGlEPTB;MUG1MlA5KM7:TR?= M1X4ZlI3PDB5NkWz
SGC-7901/DDP M{DhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInuT4QzPMLiaNMg M{S4NmlEPTB;M{WuOFUh|ryP M3rBWlI3PDB5NkWz
SGC-7901/DDP NU[3PZNvSXCxcITvd4l{KEG|c3H5 NEjQUZgyOMLiwsXN MW[yOEBp NXvGTVBlcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDD3bZRpKGOrc4DsZZRqdg>? MUmyOlQxPzZ3Mx?=
SGC-7901/DDP M4LwRWZ2dmO2aX;uJGF{e2G7 M4L5WVExyqEEtV2= M2e5S|I1KGh? M3;yVYlvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJHAu\2y7Y3;wdo91\WmwIITodo92\2hiYnzvZ4tqdmdiRWCyMEBidmRiaX7hZ5RqfmG2aX7nJHBMSSCjbnSgR3JGSsLi MXSyOlQxPzZ3Mx?=
SGC-7901/DDP MnrCSpVv[3Srb36gRZN{[Xl? NFO4Z5AyOMLiwsXN NFPjeIIzPCCq MXTjZZV{\XNiYTDtZZJs\WRiZHXjdoVie2ViaX6geIhmKGyndnXsJI9nKEKlbD2yJJBzd3SnaX6= NG[xZmYzPjRyN{[1Ny=>
H357 NGryUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHRWoJQPy53L{GwJO69VQ>? NVnNOFFsPDhiaB?= M2r5TGROW09? M4C1ZYlvcGmkaYTzJINmdGxiZ4Lve5RpyqClb33ibY5m\CC5aYToJHNi[nW2b3PsZZg> NHPkd|czPjByOUi3OC=>
TAF M4jUWGZ2dmO2aX;uJGF{e2G7 M3m2cVExyqEEtV2= MknnO{Bl NX3qeGlH[W[oZXP0d{BVSU[|IHHkbIV{cX[nIIDyc5BmenSrZYO= M4nvXVI2QTh5MUK3
TAF M4X5WGZ2dmO2aX;uJGF{e2G7 MlznNVDDqML3TR?= MWCzNE0yOjBibXnu NUTIUoVieG:xcnz5JIFn\mWldIOg[GFsfCCyaH;zdIhwenmuYYTpc44h[2:wc3XxeYVvfCC2bzDFS2Yhe2mpbnHsbY5o MmfUNlU6QDdzMke=
TAF MXnGeY5kfGmxbjDBd5NigQ>? MlrkNVDDqML3TR?= M1XHPVQ5KGh? Mnz2bY5kemWjc3XzJGVITlJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w MnLTNlU6QDdzMke=
PANC-1 MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:yNE83OC9zMECg{txO NF61fFYzPC92OD:3NkBp M4TXPIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M2\DWlI2QTd|ME[y
PANC-1 MnHFSpVv[3Srb36gRZN{[Xl? M{mySVIxNzZyL{GwNEDPxE1? NULoW|NKOjRiaB?= MX7heJRmdnWjdIOgZ4VtdCCrbo\hd4lwdiCjbnSgcYloemG2aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA> M1\FT|I2QTd|ME[y
HeLa  NWHkeFNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jYbFIxyqEQvF5CpC=> MXSyOOKhcA>? Mmnz[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25? M3uyW|I2PzdyNEKz
SACC-83 MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLVNlDDqM7:TdMg MlXoNlTDqGh? NETEU2tmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?= MXOyOVc4ODR{Mx?=
HeLa  NV7MOWZ{SXCxcITvd4l{KEG|c3H5 M4S0c|IxyqEQvF5CpC=> MlTHNlTDqGh? MXrlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygZZBweHSxc3nz MlnDNlU4PzB2MkO=
SACC-83 M1OxSWFxd3C2b4Ppd{BCe3OjeR?= NHXsN3QzOMLizszNxsA> NUfzd3VCOjUEoHi= NWDodYE3\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKGGyb4D0c5Nqew>? Mn2yNlU4PzB2MkO=
HeLa  NGr4b4lHfW6ldHnvckBCe3OjeR?= NUjmU2tHOjBxNECvPFAh|ryP NXq3enp1OjUEoHi= MoH4eZBz\We3bHH0d{BRXEWQIIDhdpRq[WyueTDifUBqdmirYnn0bY5oKFOyMTygZY5lKGGldHn2ZZRmeyCSVFXOJIFv\CCrbnHjeIl3[XSnczDBT3Q> MkHJNlU4PzB2MkO=
SACC-83 MkfNSpVv[3Srb36gRZN{[Xl? NXHrSJZPOjBxNECvPFAh|ryP NUTBeVY2OjUEoHi= NGjOO2l2eHKnZ4XsZZR{KFCWRV6gdIFzfGmjbHz5JIJ6KGmwaHnibZRqdmdiU4CxMEBidmRiYXP0bZZifGW|IGDUSW4h[W6mIHnuZYN1cX[jdHXzJGFMXA>? NUT6XIpZOjV5N{C0NlM>
HLCZ01 M3n5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W4WlDjiJN4MNMgxtVO NHXreGY1QCCq NEjhUnVFVVOR NX;3OYF6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NVzNUnZOOjV5MkS4PVk>
HLCZ01 Mn3SSpVv[3Srb36gRZN{[Xl? NIq1NGk1OMLizszN M2rjfFI1KGh? NV\6fpB{TE2VTx?= M2niNYlv[3KnYYPld{Bi[2O3bYXsZZRqd25ib3[gS|AwTzFvcHjhd4Uh[2WubIOgZ49u[mmwZXSge4l1cCCLRl6t{tE> M{i1WFI2PzJ2OEm5
HLCZ01 NGTNb21CeG:ydH;zbZMhSXO|YYm= MVW0NOKh|ryP MXOyOEBp MY\EUXNQ M1y4[4VvcGGwY3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>? M3;Qd|I2PzJ2OEm5
HLCZ01 MXvGeY5kfGmxbjDBd5NigQ>? M{K0RVQxyqEQvF2= MYeyOEBp NViwZYhCTE2VTx?= MY\pcoNz\WG|ZYOgWHJCUUxiZYjwdoV{e2mxbjDjc41jcW6nZDD3bZRpKEmwdHXy[oVzd25vzsG= M4O5[|I2PzJ2OEm5
MGC803 NIm0cmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPONE03OCEQvF2= M4nGdlczKGh? MYnJR|UxRTR5LkK15qCKyrIkgJm2MlQ{KM7:TR?= M1rYNVI2PzBzM{e4
SGC7901 MoPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7rNE03OCEQvF2= NGHvVHQ4OiCq MXzJR|UxRTR|LkWz5qCKyrIkgJm1MlEzKM7:TR?= NXX6blgyOjV5MEGzO|g>
MGC803 M3TtTGZ2dmO2aX;uJGF{e2G7 M3PaVlQxyqEQvF2= MUO4M|E3NzJ2IHi= MYj1dJJm\3WuYYTzJGNjdC2kIHX4dJJme3Orb36= M3zKU|I2PzBzM{e4
SGC7901 M2HuV2Z2dmO2aX;uJGF{e2G7 M3TPbFQxyqEQvF2= NIHOZXg5NzF4L{K0JIg> Mn36eZBz\We3bHH0d{BE[mxvYjDlfJBz\XO|aX;u M365U|I2PzBzM{e4
MCF-7  M3nZb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGxM|ExKM7:TR?= MVK3NkBp MX\EUXNQ MWTlcohidmOnczDjZYxkcXS{aX;sMYlv\HWlZXSgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdg>? M{jpZVI2PjZ5NUGw
MDA-MB-231  NYT6dJBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\KfXZQOS9zMDFOwG0> MX[3NkBp NFTt[mNFVVOR NV\xSmdw\W6qYX7j[ZMh[2GuY3n0dolwdC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36= NVy2S4s3OjV4Nke1NVA>
MDA-MB-231 MnXrSpVv[3Srb36gRZN{[Xl? M3\jeFAuPDBiwsXN MmLCOE0zPCCq MkS2bY5kemWjc3XzJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NUHsVnF{OjV3OEezNlk>
MCF-7 M2\pSGZ2dmO2aX;uJGF{e2G7 NHmweIExNTRyINM1US=> M1rHflQuOjRiaB?= NI\hPGRmdmijbnPld{B1cGViZX\m[YN1eyCxZjDUVGEhd25iQVLDS|Ih\XiycnXzd4lwdsLi NFPiPVAzPTV6N{OyPS=>
MCF7-MX  MlLXSpVv[3Srb36gRZN{[Xl? MXSwMVQxKML3TR?= NVvsOZlkPC1{NDDo MYLlcohidmOnczD0bIUh\W[oZXP0d{Bw\iCWUFGgc44hSUKFR{Kg[ZhxemW|c3nvcuKh Mn7ZNlU2QDd|Mkm=
MDA-MB-231 MV7GeY5kfGmxbjDBd5NigQ>? MVmwMVQxKML3TR?= M33pO|QuOjRiaB?= NE[5OXl{fGmvdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKEGEQ1eyJJVxKHSxIESuNlchfGmvZYOgeI8h[2:wdILvcEBt\X[nbDDifUAyOiCqwrC= MonDNlU2QDd|Mkm=
A2780 NXTBSW9uTnWwY4Tpc44hSXO|YYm= NVrtOW1GPS9zMD:xOUDPxE1? MmTDOFghcA>? NH7DZ4Rl\WO{ZXHz[ZMhS2:6LUKg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MmDvNlU1OjR6OUi=
SKOV3  M3PLUGZ2dmO2aX;uJGF{e2G7 Mme2OU8yOC9zNTFOwG0> NUj1V|JuPDhiaB?= NGX1TXpl\WO{ZXHz[ZMhS2:6LUKg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NF;1NVIzPTR{NEi5PC=>
A2780 M4rBPWZ2dmO2aX;uJGF{e2G7 M2XxOlUwOTBxMUWg{txO NGL4bGs1QCCq MVzlcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv M2qyPFI2PDJ2OEm4
SKOV3  NIjJUpFHfW6ldHnvckBCe3OjeR?= NVOx[JhyPS9zMD:xOUDPxE1? MkLTOFghcA>? Mkiw[YxmfmG2ZYOgeIhmKGW6cILld5Nqd25ib3[gSU1k[WSqZYLpckBidmRia3XyZZRqdg>? MX[yOVQzPDh7OB?=
A2780 MmCzSpVv[3Srb36gRZN{[Xl? MUO1M|ExNzF3IN88US=> M2G3RlQ5KGh? NI[3Xm1l\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVi2lYXTo[ZJqdiCjbnSgWolu\W62aX6= NHe2NG4zPTR{NEi5PC=>
SKOV3  MnX1SpVv[3Srb36gRZN{[Xl? NUHyeZhJPS9zMD:xOUDPxE1? NUS2OpRjPDhiaB?= M1jROIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBPNWOjZHjldolvKGGwZDDWbY1mdnSrbh?= Mmq3NlU1OjR6OUi=
A2780 MoH2SpVv[3Srb36gRZN{[Xl? MYe1M|ExNzF3IN88US=> NILXU3oyKGh? MmC0bY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXqyOVQzPDh7OB?=
SKOV3  NFjZNmlHfW6ldHnvckBCe3OjeR?= MknzOU8yOC9zNTFOwG0> M2DXVFEhcA>? MmX5bY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2S3SlI2PDJ2OEm4
HCT-15 MUHGeY5kfGmxbjDBd5NigQ>? M3f1OlExNTVyIN88US=> NWPtTotpPi1|NjDo MUPpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ NUe3RYQ6OjV{MUiwNlg>
HT-29  NInJVWJHfW6ldHnvckBCe3OjeR?= NHK3UoEyOC13MDFOwG0> NHTD[pc3NTN4IHi= NH\SfXBqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy MYiyOVIyQDB{OB?=
HSC3  MljzR4VtdCCYaXHibYxqfHliQYPzZZk> NETUXXQx6oDVNECg{txO MojYOFghcA>? M2jrT2lEPTB;MkWuOeKyOS55OECg{txO NYrlXmNlOjVzOUi3PFk>
HSC3  M{T4PWFxd3C2b4Ppd{BCe3OjeR?= MnjqNlUh|ryP MUW0PEBp NVv5cnNlcW6mdXPld{BieG:ydH;zbZM> M{G2dVI2OTl6N{i5
HSC3  M4\OWmZ2dmO2aX;uJGF{e2G7 NXTGSZJuOjVizszN M4DqbVQ5KGh? NGfqOFhmgGirYnn0d{B{cWewaX\pZ4FvfGy7IILl[JVk\WRibXnndoF1cW:wIHPvcYJqdmWmIIfpeIghS0WW MnX4NlUyQTh5OEm=
HSC3  NGDHbZFHfW6ldHnvckBCe3OjeR?= M2r6dlI2KM7:TR?= MUe0PEBp MXHpcohq[mm2czDIV2M{KGOnbHygbY53[XOrb36gZ49u[mmwZXSge4l1cCCFRWS= NF3zcWszPTF7OEe4PS=>
HSC3  MmDwSpVv[3Srb36gRZN{[Xl? Mn\UNlUh|ryP Mn31O|IhcA>? NGXOe5Fl\WO{ZXHz[ZMhVU2SLUKgZY5lKE2PUD25JJBzd3SnaX7zxsA> NYH4dnVJOjVzOUi3PFk>
201T  M1z2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz2VG0yPzJiaB?= MXvEUXNQ NGns[YVKSzVyPUS4MlYhyrWP Ml3JNlUxPTd7NEG=
273T M{\NbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\nVog4OiCq NUf2N|E3TE2VTx?= NVPld4dJUUN3ME24NE42KML3TR?= M1\5U|I2ODV5OUSx
Hep-2 NYm3dmM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XJbVMxNzVyL{GwNEDPxE1? NVfy[GlQOTJxMkSvN|YwPDhiaB?= NFvzWJNFVVOR MkHEbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MXeyOFk6QDV4NB?=
Hep-2 NGXQc5BCeG:ydH;zbZMhSXO|YYm= MVO1NEDPxE1? Mm\2NE01QCCq M4qzfWROW09? NVnhOFA{cW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MX6yOFk6QDV4NB?=
Hep-2 MUTGeY5kfGmxbjDBd5NigQ>? MnXyOVAh|ryP NYn3Toc3OC12ODDo NV\o[WtUTE2VTx?= NWnkeWU5emWmdXPld{B1cGVidHXsc41memG|ZTDhZ5Rqfmm2eTDndoFlfWGubIm= MYWyOFk6QDV4NB?=
Hep-2 M3;TfGZ2dmO2aX;uJGF{e2G7 NXjEPYs4PTBizszN M3;Ve|AuPDhiaB?= NF;V[o5FVVOR NV3QO5lW\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gbHRGWlR? MXSyOFk6QDV4NB?=
SGC-7901 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXYVJMyOC93MD:xNFAh|ryP M3iwUVI1NzR6L{eyJIg> NEPjeW1FVVOR M3nNWolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NUHzfmRIOjR7OUK5OVg>
MKN-45 NX2wb5d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXuRnFLOTBxNUCvNVAxKM7:TR?= MXyyOE81QC95MjDo M{nzWmROW09? M3PRb4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NHLnRVQzPDl7Mkm1PC=>
SGC-7901 MmHsSpVv[3Srb36gRZN{[Xl? NX[3W2ZTOTBxNUCvNVAxKM7:TR?= MX60PEBp NFLnbmNFVVOR NH;RRo1ld3ewcnXneYxifGW|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJGNQYC1{IHHu[EBRS06DIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NX7zOFZkOjR7OUK5OVg>
MKN-45 M{jRc2Z2dmO2aX;uJGF{e2G7 MXixNE82OC9zMECg{txO NWTle3o1PDhiaB?= M{HpPGROW09? NF:2cW9ld3ewcnXneYxifGW|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJGNQYC1{IHHu[EBRS06DIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MknaNlQ6QTJ7NUi=
C666-1 MXXDfZRwfG:6aXPpeJkhSXO|YYm= Mkj3NlAuQDBizszN MXiyOEBp MkC0[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> M1m5blI1QDV2OEO4
CNE-1 MnP0R5l1d3SxeHnjbZR6KEG|c3H5 MlTTNlAuQDBizszN MUOyOEBp NYPrSI5p\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? M1P5XVI1QDV2OEO4
CNE-2 MlrXR5l1d3SxeHnjbZR6KEG|c3H5 M3zzclIxNThyIN88US=> MkO0NlQhcA>? NFr0fFJl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh NGXHcpIzPDh3NEizPC=>
C666-1 M2Xjd2N6fG:2b4jpZ4l1gSCDc4PhfS=> M1jBNVYxKM7:TR?= MXu3JIQ> Ml70[Y5p[W6lZYOgdoFlcWG2aX;uJIN6fG:2b4jpZ4l1gSC2aILveYdpKEORWD2yMYRmeGWwZHXueEBu[W6wZYK= MWKyOFg2PDh|OB?=
CNE-1 M1i5fmN6fG:2b4jpZ4l1gSCDc4PhfS=> NWnlVVJyPjBizszN NV;TU2J5PyCm M4[5XoVvcGGwY3XzJJJi\GmjdHnvckBkgXSxdH;4bYNqfHlidHjyc5VocCCFT2itNk1l\XCnbnTlcpQhdWGwbnXy NF21SoUzPDh3NEizPC=>
SNU-1041 NFvEOmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzNXW4xNTRyIN88US=> MoflOFghcA>? NGjKe2ZqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= Ml;GNlQ3QTJ5MEO=
SNU-1041 M{PKe2Z2dmO2aX;uJGF{e2G7 NVu4fYhUOjBxM{Cg{txO NFXtNZY1KGh? NXnDOIpbcW6mdXPld{BmgHC{ZYPzbY9vKG:owrDDTG9RNCCJUmC3POKh[W6mwrDYRnAyyqCjdDD0bIUhWk6DIHzleoVtyqB? NHj2emgzPDZ7MkewNy=>
SNU-1041 M{PE[GZ2dmO2aX;uJGF{e2G7 NHu3V|gxNTRyIN88US=> NWrnS3F6PCCq M3GxepVxNXKnZ4XsZZRmeyCFSF;QxsBi\nSncjD0doVifG2nboSge4l1cCCqaXfoJINwdmOnboTyZZRqd26| M1vjN|I1Pjl{N{Cz
SGC-7901 M{fkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDWc5VCPTBvMUK1JO69VQ>? NUDONJJNOjRxNEivO|IhcA>? MWHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NHTBepgzPDZ5NkO5OC=>
SGC-7901 M1\QcmFxd3C2b4Ppd{BCe3OjeR?= MmeyNVAxKM7:TR?= NITN[WI4OiCq MUXpcoR2[2W|IHHwc5B1d3Orcx?= MX2yOFY4PjN7NB?=
SGC-7901 MVHGeY5kfGmxbjDBd5NigQ>? NYnScHU3PzVxMUCwM|EzPSEQvF2= M4P3clI1NzR6L{eyJIg> MmPNbY5kemWjc3XzJINie3Cjc3WtPEBidmRiLUmgcXJPSSCneIDy[ZN{cW:wIHnuJIJwfGhidHnt[UBidmRiZH;z[UBu[W6wZYK= NH\3b4IzPDZ5NkO5OC=>
LMeC  MWrGeY5kfGmxbjDBd5NigQ>? NUPtcFc5OjBxNUCg{txO MljYOFghcA>? M4OxZYRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDwdo91\Wmw Mnn6NlQ3PTZ5NE[=
CMeC-1 NXXBdIQ1S2WubDDWbYFjcWyrdImgRZN{[Xl? NW\0UXNjOjBxNUCg{txO NH3KTYc1QCCq MVPpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NHvueYUzPDZ3Nke0Oi=>
LMeC NWPnUoZTS2WubDDWbYFjcWyrdImgRZN{[Xl? MYOyNE82OCEQvF2= MUW0PEBp MknSbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MXSyOFY2Pjd2Nh?=
CMeC-1 MUDGeY5kfGmxbjDBd5NigQ>? MoTsNlAwPTBizszN MXG0PEBp M{HaPIlv\HWlZYOgS|EuWyCjcoLld5Q> NGSyV2kzPDZ3Nke0Oi=>
LMeC NVXqbYc1TnWwY4Tpc44hSXO|YYm= MlTtNlAwPTBizszN NF6xTIY1QCCq NX[3Umh{cW6mdXPld{BIOS2VIHHydoV{fA>? MXSyOFY2Pjd2Nh?=
CMeC-1 M{HQO2Z2dmO2aX;uJGF{e2G7 M1HzblIxNzVyIN88US=> NUi0cotGPDhiaB?= Ml20[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZiY4njcIlvKERzIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NELTOmEzPDZ3Nke0Oi=>
LMeC NGHh[pRHfW6ldHnvckBCe3OjeR?= NGTCPFgzOC93MDFOwG0> MmPlOFghcA>? NF;EeY5l\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjfYNtcW5iREGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M2CyT|I1PjV4N{S2
CMeC-1 MkjXSpVv[3Srb36gRZN{[Xl? NILPcVAzOC93MDFOwG0> Ml\wOFghcA>? MoPTbY5lfWOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> MXSyOFY2Pjd2Nh?=
LMeC M4ewVGZ2dmO2aX;uJGF{e2G7 NX7td2V1OjBxNUCg{txO NIjIbok1QCCq M2LLV4lv\HWlZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> NFyycJkzPDZ3Nke0Oi=>
OVCAR-3 NVKyVYRYS2WubDDWbYFjcWyrdImgRZN{[Xl? M2fXTFExKML3TR?= NIi5b4IyKGh? NFztR2RmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKh MXqyOFUzODJ{Nx?=
OVCAR-3 M1TxSWFxd3C2b4Ppd{BCe3OjeR?= MUSxNEDDvU1? NX;FVWlOOSCq NUe3TolDeHKxbX;0[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGyb4D0c5Nqe8Li MkmyNlQ2OjB{Mke=
OVCAR-3 M120WmZ2dmO2aX;uJGF{e2G7 NHewSJMyOCEEtV2= NYPyN2ptOSCq M3vKZ4VvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2VvOdMg MmHoNlQ2OjB{Mke=
OVCAR-3 NXPSVVMzTnWwY4Tpc44hSXO|YYm= NH;OR2MyOCEEtV2= NF\TfGMyKGh? M2SyXIRwf25vcnXneYxifGW|IF7GMe67SiCjY4TpeoF1cW:wIHnu[JVk\WRiYomgdIFkdGm2YYjlcC=> M3nuXVI1PTJyMkK3
OVCAR-3 NXjs[49GTnWwY4Tpc44hSXO|YYm= NUnIbJFIOTBiwsXN NUX5VmRXOSCq MYDpcohq[mm2czDwZYNtcXSjeHXsMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=> M1rzfVI1PTJyMkK3
CF33 M1qxR2Z2dmO2aX;uJGF{e2G7 Mly5NVAxKM7:TR?= NED4UGUzPCCq NVjLdIZNcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBEV1hvMjDwdo91\WmwIHX4dJJme3Orb36= NEfYcVczPDVyM{e4Ni=>
CF33 MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuxNE0yODBizszN NWnIO4pHOC12IHS= MYDpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MmPjNlQ2ODN5OEK=
CF33 NHfWcGNHfW6ldHnvckBCe3OjeR?= NVjZc2pSOTBvMUCwJO69VQ>? M1TaVVQuOjRiaB?= MWnk[YNz\WG|ZYOgZ4VtdHNiaX6geIhmKFNicHjhd4Uh[W6mIHnuZ5Jm[XOnczDj[YxteyCrbjDHNE9IOSCjcoLld5Q> NHLwNWozPDVyM{e4Ni=>
LNCaP NH71PZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjsNk82NzFyIN88US=> NG[4R|U6PiCq NYXWTpM6cW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> M2C2dFI1Ojl4OUe4
LNCaP M{XkOmFxd3C2b4Ppd{BCe3OjeR?= NGPFUJUzNzVxMUCg{txO NGjPN|E6PiCq MojGbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCjdH;yeoF{fGG2aX6= MYiyOFI6Pjl5OB?=
PC-3  NV[1R2dzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPoWJNXOC13MDFOwG0> MlLFOFjjiImq NVLoWoZCcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NIHLPFYzPDF{N{i4Ni=>
PC-3  M{TCV2NmdGxiVnnhZoltcXS7IFHzd4F6 MX6wMVExOCEQvF2= MVS3NkBp NGjSTJBl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MkO2NlQyOjd6OEK=

... Click to View More Cell Line Experimental Data

In vivo試験 Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]
臨床試験 Celecoxib is currently in Phase II clinical trials in patients with recurrent respiratory papillomatosis.
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

COX enzyme assay in vitro Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.

細胞アッセイ: [2]

細胞株 HNE1 and CNE1-LMP1
濃度 0-75 μM
反応時間 48 hours
実験の流れ The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.

動物実験: [1]

動物モデル A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
製剤 Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
投薬量 ≤200 mg/kg
投与方法 Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Celecoxib SDF
分子量 381.37
化学式

C17H14F3N3O2S

CAS No. 169590-42-5
保管 2年-20℃
6月-80℃in solvent
別名 SC 58635
溶解度 (25°C) * In vitro DMSO 76 mg/mL (199.28 mM)
エタノール 33 mg/mL (86.53 mM)
<1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-(5-p-tolyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide

文献中の引用 (6)

Frequently Asked Questions

  • Question 1
    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

    Answer: For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related COX 阻害剤

  • Xanthohumol

    Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Phase 1.

  • AZD3839

    AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.

  • A-438079 HCl

    A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.

  • PF-03084014 (PF-3084014)

    PF-03084014 (PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay. Phase 2.

  • Indomethacin

    Indomethacin(Indocid, Indocin) is a non-steroidal anti-inflammatory compound commonly used to reduce fever, pain, stiffness, and swelling.

  • Lornoxicam

    Lornoxicam is a COX-1 and COX-2 inhibitor with IC50 of 5 nM and 8 nM, respectively.

  • Aspirin

    Aspirin is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication.

  • Rofecoxib

    Rofecoxib is a COX-2 inhibitor with IC50 of 18 nM.

  • Ketorolac

    Ketorolacは非選択COX阻害剤、人間COX-1とCOX-2に作用する時、IC50がそれぞれ1.23 µM と3.50 µM になる。

    Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).

最近チェックしたアイテム

Tags: Celecoxibを買う | Celecoxib供給者 | Celecoxibを購入する | Celecoxib費用 | Celecoxib生産者 | オーダーCelecoxib | Celecoxib代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ